Adocia to Present Positive Clinical Results for BioChaperone® Lispro at the American Diabetes Association 75th Scientific Sessions on June 6th 2015

A poster disclosing final results for the dose-response study of the ultra rapid insulin, BioChaperone Lispro, has been selected by the American Diabetes Association (ADA)

Lyon, France, May 28, 2015 - Adocia (Euronext Paris: FR0011184241 - ADOC) announced today that a poster on the company’s research in diabetes has been accepted for presentation at the 75th Scientific Sessions of the American Diabetes Association (ADA) to take place in Boston, MA from June 5 – 9.

The annual meeting of the ADA is the largest worldwide scientific meeting for clinicians and researchers in diabetes. During this meeting, Dr. Tim Heise, MD (Profil Neuss), medical advisor to Adocia for insulins programs, will present a poster on final phase Ib clinical results of Adocia’s ultra rapid insulin, BioChaperone® Lispro. In December 2014, Adocia signed a partnership with Eli Lilly and Company for the development and commercialization of BioChaperone Lispro.

"We are very pleased to share the complete clinical data for the 2014 dose response study on BioChaperone Lispro. These results further confirm the potential of our ultra rapid insulin to fulfill unmet needs in the prandial insulin space,” said Olivier Soula, R&D Director and Deputy General Manager of Adocia.

BioChaperone Lispro is an ultra rapid formulation of insulin lispro (Lilly’s Humalog®), which aims to improve prandial glycemic control for patients on insulin therapy. BioChaperone Lispro presents an action profile closer to the physiological prandial insulin response compared to insulin analogs. Adocia will present detailed Pharmacokinetic (PK) and Pharmacodynamic (PD) profiles for this product tested at three different insulin doses. These profiles have been obtained in a phase Ib clinical trial conducted on 36 type 1 diabetics versus Humalog.

Presentation of the poster 979-P “Ultra-Rapid BioChaperone Insulin Lispro (BC LIS): Linear Dose-Response and Faster Absorption than Insulin Lispro (LIS)” in category 01-B Clinical Therapeutics/New Technology–Insulins. It will be displayed for three days (Saturday, Sunday, and Monday) in the Poster Hall.
This poster has also been selected by the Scientific Sessions Meeting Planning Committee to be showcased in a Guided Audio Poster Tour entitled, “Working to Improve Mealtime Insulin Therapy” on **Sunday, 7 June 2015, 13:00 - 14:00 EDT time.**

**About the ADA Scientific Sessions**

The annual meeting of the ADA is the largest diabetes meeting in the world, bringing together nearly 18,000 participants — including more than 14,000 clinicians and researchers from the U.S. and 117 countries. The 5-day annual meeting features timely and significant advances in basic science and the prevention, diagnosis, and treatment of diabetes. There are over 3,000 original presentations which include symposia, oral abstract sessions, meet the expert sessions, interest group discussions, guided audio poster tours, and poster presentations. It also includes approximately 175 exhibitors showcasing the latest developments in terms of products, services, and technology available to healthcare professionals for diabetes treatment. For more information, go to [http://www.diabetes.org](http://www.diabetes.org).

**About diabetes**

Diabetes is a chronic condition in which the person has high blood glucose (hyperglycemia), either because insulin production is inadequate, or because the body's cells do not respond properly to insulin, or both. Over time, chronic hyperglycemia contributes to disease progression and results in macrovascular and microvascular complications. Worldwide, more than 382 million individuals are currently suffering from diabetes, with a forecast of 592 million individuals by 2035, i.e. an average increase of 55%, and an increase of as much as 70% in emerging countries. (Source: International Diabetes Federation, 2013). All type 1 diabetic patients require insulin to manage their disease. In the case of type 2 diabetes, disease intensification also leads most patients to use insulin.

**About Adocia**

*To be a global leader in the innovative delivery of insulins and therapeutic proteins*

Adocia is a clinical stage biotechnology company that specializes in the development of innovative formulations of already approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. Adocia’s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.

In December 2014, Adocia signed a partnership with Eli Lilly and Company for the development and commercialization of its new formulation of insulin lispro, BioChaperone Lispro, previously tested successfully in two phase Ib studies.

Adocia will continue to develop its fast-acting human insulin formulation internally. Two clinical studies are planned over 2015, a post-meal glucose control study with HinsBet U100 and a PK/PD study with HinsBet U500. Adocia is also actively continuing the development of its BioChaperone Combo, a unique combination of insulin Glargine, the gold-standard of basal insulin and insulin lispro, a fast-acting insulin analog. Two Phase IIa clinical studies are scheduled for the second quarter 2015, one which is a glycemic control after a standardized meal with type 1 diabetic patients, the other clinical study is about pharmacodynamics in euglycemic clamp with type 2 diabetic patients. A dose-response clinical study in type 1 diabetic patients is also scheduled for the fourth quarter of 2015.

In addition, Adocia launched a phase III clinical study in India on its product based on PDGF-BB for treatment of the diabetic foot ulcer (BioChaperone PDGF-BB) in August 2014.

Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold-standard biologics for the treatment of various chronic pathologies (cancer, inflammation, etc.). Adocia is engaged in collaborative programs with two major pharmaceutical companies in this field.
**Fighting cancer with targeted treatments**

DriveIn® is a nanotechnology which is intended to significantly improve delivery of active compounds into cancer cells. This new proprietary platform constitutes an exceptional opportunity to enter the oncology market by improving the efficacy of both already approved treatments and novel proprietary molecules.

### « Innovative medicine for everyone, everywhere »

Adocia’s therapeutic innovations aim to provide solutions in a profoundly changing global pharmaceutical and economic context, characterized by (i) an increased prevalence and impact of the targeted pathologies, (ii) a growing and ageing population, (iii) a need to control public health expenditures and (iv) an increasing demand from emerging countries.

Adocia is listed on the regulated market of Euronext in Paris (ISIN: FR0011184241; Reuters/Bloomberg ticker: ADOC, ADOC.PA, ADOC.FP) and is included in the Next Biotech index.

American Depositary Receipts representing Adocia common stock are traded on the US OTC market under the ticker symbol ADOCY.

For more information, visit: [www.adocia.com](http://www.adocia.com)

---

**For more information please contact:**

<table>
<thead>
<tr>
<th><strong>Adocia</strong></th>
<th><strong>Adocia Press Relations</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gérard Soula</td>
<td>ALIZE RP</td>
</tr>
<tr>
<td>Chairman and CEO of Adocia</td>
<td>Caroline Carmagnol</td>
</tr>
<tr>
<td><a href="mailto:contactinvestisseurs@adocia.com">contactinvestisseurs@adocia.com</a></td>
<td><a href="mailto:caroline@alizerp.com">caroline@alizerp.com</a></td>
</tr>
<tr>
<td>Tel.: +33 4 72 610 610</td>
<td><a href="mailto:adocia@alizerp.com">adocia@alizerp.com</a></td>
</tr>
<tr>
<td></td>
<td>Tel.: + 33 1 44 54 36 61</td>
</tr>
</tbody>
</table>

**Disclaimer**

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the ‘Risk Factors’ section of the Reference Document registered by the Autorite des marches financiers on April 30 2015 under number R.15-032 (a copy of which is available on http://www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.